clinical trial · NCT06693895
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
GlaxoSmithKline·phase3·recruiting·n = 750
ChickenpoxInvestigational varicella vaccineMarketed varicella vaccineMeasles, mumps, and rubella vaccineHepatitis A vaccinePCV (pneumococcal conjugate vaccine) 13PCV 20Vaxneuvance
brief summary
The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.
started
Nov 26, 2024
primary completion
Jul 1, 2026
completion
Nov 23, 2026
last updated
Jan 20, 2025
official title
A Phase 3a, Observer-blind, Randomized, Controlled Study to Evaluate the Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol